NCT00051129View on ClinicalTrials.gov

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

PHASE3CompletedINTERVENTIONAL
Enrollment

291

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Macular DegenerationMaculopathy, Age-RelatedAge-Related MaculopathiesAge-Related MaculopathyMaculopathies, Age-Related
Interventions
DRUG

Anecortave Acetate 15 mg sterile suspension

0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection

OTHER

Anecortave Acetate Vehicle

Administered as a posterior juxtascleral injection

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY